仅附件转移的低级别子宫内膜样子宫内膜癌:辅助治疗降阶梯的评估
该回顾性研究基于美国国家癌症数据库2010-2015年数据,评估IA3期与IIIA1期子宫内膜癌的生存结局及辅助治疗与生存的关联。IA3期患者无论是否接受辅助治疗,总生存均较好,尤其1级病变,部分支持FIGO委员会关于IA3期辅助治疗降阶梯的建议;而IIIA1期省略辅助治疗与总生存下降相关。
要点
- IA3期子宫内膜癌未接受辅助治疗者5年总生存率为86.3%,与联合治疗组的91.4%相比无显著差异(aHR 1.23,95%CI 0.70-2.18)。
- IA3期1级病变患者中,联合治疗、单纯化疗和未辅助治疗的5年总生存率分别为96.2%、89.4%和100%。
- IIIA1期省略辅助治疗与总生存下降相关:与联合治疗相比5年总生存率43.2% vs 73.1%(aHR 1.65,95%CI 1.30-2.11)。
核心结论
- 研究结果提示,辅助治疗对IA3期和IIIA1期子宫内膜癌的生存效应不同。
- IA3期患者无论是否接受辅助治疗总生存均较好,尤其1级病变,部分支持FIGO委员会关于IA3期子宫内膜癌辅助治疗降阶梯的建议。
- IIIA1期省略辅助治疗与总生存下降相关。
研究设计与样本
- 回顾性查询美国国家癌症数据库,纳入2010-2015年IA3期子宫内膜癌594例和IIIA1期1455例。
- 按辅助治疗方式分为联合化疗与外照射放疗、单纯化疗、单纯外照射放疗和未辅助治疗,比较总生存。
主要发现
- IA3期109例(18.4%)未接受辅助治疗;未辅助治疗组与联合治疗组5年总生存率分别为86.3%和91.4%(aHR 1.23,95%CI 0.70-2.18)。
- IA3期未辅助治疗组与单纯化疗组5年总生存率均为86.3%(aHR 1.11,95%CI 0.67-1.83)。
- 接受淋巴结评估的IA3期患者中,联合治疗、单纯化疗和未辅助治疗的5年总生存率分别为92.6%、86.6%和89.4%。
- IA3期1级病变中,联合治疗、单纯化疗和未辅助治疗的5年总生存率分别为96.2%、89.4%和100%。
- IA3期2级病变中,未辅助治疗组5年总生存率较联合治疗组略低(联合治疗89.4%、单纯化疗84.0%、未辅助治疗82.7%,P=0.03)。
临床怎么用
- 作者认为,IA3期患者无论是否接受辅助治疗总生存均较好,尤其1级病变,部分支持FIGO委员会关于IA3期子宫内膜癌辅助治疗降阶梯的建议。
- 研究结果提示,辅助治疗对IA3期和IIIA1期子宫内膜癌的生存效应不同。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess survival outcomes of stage IA3 endometrial cancer and the association of adjuvant therapy and survival. METHODS: The National Cancer Database was retrospectively queried to examine 594 and 1455 patients with stage IA3 and IIIA1 endometrial cancer, respectively, from 2010-2015. Overall survival (OS) was examined based on adjuvant therapy: multimodal combination chemotherapy and external beam radiotherapy, chemotherapy alone, external beam radiotherapy alone, and none. RESULTS: For stage IA3 disease, 109 (18.4%) patients did not receive adjuvant therapy. The 5-year OS rates for the no adjuvant therapy group and the combination group were 86.3% and 91.4%, respectively (adjusted-hazard ratio [aHR] 1.23, 95% confidence interval [CI] 0.70-2.18). This survival association was consistent when compared to chemotherapy alone (5-year OS rates 86.3% vs 86.3%, aHR 1.11, 95%CI 0.67-1.83). The results were similar among those who underwent nodal evaluation (5-year OS rates, 92.6%, 86.6%, and 89.4% for combination therapy, chemotherapy alone, and no adjuvant therapy), including grade 1 lesions (96.2%, 89.4%, and 100%, respectively). In grade 2 lesions, 5-year OR rates was modestly lower for no adjuvant therapy than combination therapy (89.4%, 84.0%, and 82.7% for combination, chemotherapy alone, and no adjuvant therapy, P = 0.03). For stage IIIA1 disease, omission of adjuvant therapy was associated with decreased OS compared to combination therapy (43.2% vs 73.1%, aHR 1.65, 95%CI 1.30-2.11) or chemotherapy alone (43.2% vs 67.1%, aHR 1.62, 95%CI 1.32-1.99). CONCLUSION: The results of this investigation suggest that survival effects of adjuvant therapy differ for stage IA3 and IIIA1 diseases. Patients with stage IA3 disease have overall good prognosis regardless of adjuvant therapy particularly grade 1 lesions, partly supporting the FIGO committee suggestion for adjuvant therapy de-escalation in stage IA3 endometrial cancer.
引用
- Matsuo K, Chen L, Neuman MK, et al. Low-grade endometrioid endometrial cancer with adnexal only metastasis: Evaluation of de-escalation of adjuvant therapy. Eur J Cancer. 2024. PMID: 38309016. doi:10.1016/j.ejca.2024.113533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。